Regeneron Pharmaceuticals (NASDAQ:REGN) Releases Quarterly Earnings Results, Beats Expectations By $3.65 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) posted its quarterly earnings data on Friday. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $16.42 by $3.65, FiscalAI reports. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.56 billion. During the same quarter last year, the firm posted $11.83 earnings per share. The business’s quarterly revenue was up 36.3% on a year-over-year basis.

Here are the key takeaways from Regeneron Pharmaceuticals’ conference call:

• Regeneron reported a strong third quarter, with total revenue up 36% to $5.1 billion and non-GAAP EPS up 70% to $20.07. Dupixent, EYLEA HD, and LIBTAYO each reached record quarterly sales.
• Dupixent sales grew 35% globally at constant currency to $6.5 billion, while U.S. EYLEA HD sales rose 62% to approximately $700 million and LIBTAYO sales increased 51% globally. Management expects continued EYLEA HD momentum and anticipates a potential prefilled-syringe approval before year-end.
• The pipeline produced encouraging data across several potential growth drivers, including approximately 70% liver-fat reduction for the genetically validated CIDEB siRNA, roughly 70% response rates for ubamatamab in low-grade serous ovarian cancer, and planned pivotal development for POTS and multiple myeloma programs.
• Regeneron expanded its Sanofi alliance to develop four next-generation, longer-acting type 2 inflammation antibodies, with Regeneron recording a $1 billion upfront payment in the fourth quarter and sharing future development costs and global profits equally.
• EYLEA’s U.S. sales fell 41% year over year to $400 million, with further low- to mid-teens sequential demand declines expected in the fourth quarter as aflibercept biosimilar competition increases. Regeneron also expects 2027 R&D expense to rise by a mid-teens percentage as it advances more than 15 Phase III trials.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $108.99 during trading hours on Friday, reaching $927.76. The stock had a trading volume of 2,276,224 shares, compared to its average volume of 819,198. Regeneron Pharmaceuticals has a twelve month low of $591.52 and a twelve month high of $935.35. The company has a market cap of $95.52 billion, a price-to-earnings ratio of 22.93, a PEG ratio of 1.37 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The business’s fifty day moving average is $791.28 and its two-hundred day moving average is $737.25.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 results significantly exceeded expectations: Revenue rose 36.3% year over year to $5.12 billion, versus the $4.56 billion consensus estimate. Non-GAAP EPS increased 70% to $20.07, beating expectations by roughly $3.65, while GAAP EPS rose 35% to $18.45. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Dupixent remained the primary growth engine. Global Dupixent sales, recorded by partner Sanofi, increased 35% to $6.5 billion, comfortably exceeding market expectations and reinforcing the strength of Regeneron’s immunology franchise. Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts
• Positive Sentiment: Other key products also delivered strong growth: U.S. EYLEA HD sales increased 62% to $699 million, and Libtayo global sales rose 51% to $550 million. Management said the company is positioned for one of its strongest years, helping drive investor enthusiasm. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and partnership catalysts improved the outlook. Regeneron expanded its Sanofi collaboration to include next-generation, long-acting immunology antibodies, including a $1.0 billion upfront payment, and advanced a Phase 2 cemiplimab combination study in skin cancer. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: The stock’s move places it near a 52-week high, while analyst price-target changes have been mixed. Investors will likely focus on upcoming FDA decisions and continued execution across the pipeline. Regeneron Q3 2026 Earnings Call Transcript
• Negative Sentiment: Competition from biosimilars remains a risk for the older EYLEA 2 mg franchise, although management reported that sales have been resilient and EYLEA HD is growing rapidly.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares of the company’s stock, valued at approximately $11,163,900. This represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on REGN shares. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a “sector perform” rating in a research note on Thursday, October 8th. Sanford C. Bernstein upped their price objective on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a “market perform” rating in a report on Friday, August 14th. Finally, The Goldman Sachs Group increased their price objective on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $847.90.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.